At a glance
ClinicalIndex Comparison Record- ✓Confirmed diagnosis of multiple myeloma
- ✓Measurable disease: serum monoclonal spike >1 g/dL or urine spike >200 mg/24 hours
- ✓Karnofsky performance status >60
- ✓Hemoglobin >8.0 g/dL
- ✕Prior systemic chemotherapy (treatment-naïve required)
- ✕POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes)
- ✕Plasma cell leukemia
- ✕Creatinine clearance <30 mL/min within 14 days of enrollment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating bortezomib for Multiple Myeloma. Completed, enrolled 66 participants across 6 sites.
Detailed Summary
Bortezomib (Velcade) has just recently been approved by the FDA for the treatment of multiple myeloma in patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. This study will determine if Velcade is effective in treating patients with multiple myeloma that have had no prior treatment for the disease. We will also use whole-genome scanning to identify drug response biomarkers in bone marrow samples as well as nerve fiber studies to compare nerves prior to the use of Velcade and after treatment with Velcade.